Lilly's drug shows benefit in episodic and chronic migraine

17 June 2020

Latest research findings show Emgality (galcanezumab-gnlm), which received regulatory approval in the USA and Europe in 2018, reduces total pain burden in a recent analysis of patients with episodic and chronic migraine.

Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severity of migraine. Additionally, total pain burden demonstrated significant associations with patient functioning and quality of life.

The drug’s maker, Eli Lilly (NYSE: LLY), says Emgality is the first and only migraine preventive calcitonin gene-related peptide (CGRP) medication to be assessed in this manner, providing a more complete picture of how Emgality reduced frequency, duration, and severity of migraine pain.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK